Medroxyprogesterone Acetate Injection Recalled for Sterility Assurance
Ideal Specialty Apothecary is recalling Medroxyprogesterone Acetate Injection due to lack of assurance of sterility. The recall affects approximately 57,994 vials distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a sterile injectable drug product. Lack of sterility assurance in injectable medications poses a risk of serious infection or injury, meeting the Severe classification criteria even though no illnesses have been reported in the source text.
Plain-English summary
Ideal Specialty Apothecary, Inc. dba Ideal Pharmacy is recalling Medroxyprogesterone Acetate Injection, IM, 150 mg/mL, packaged in 1 mL single dose vials. The recall applies to all lots within expiry.
The product is being recalled because the manufacturer cannot assure the sterility of the medication. Medroxyprogesterone Acetate is an injectable contraceptive and hormone therapy drug that must meet strict sterility requirements to be safe for injection.
The affected product was distributed nationwide in the USA. The recall includes approximately 57,994 vials. Patients who have received this product should consult their healthcare provider about whether they need follow-up care or an alternative product.
The recalled product
- Product
- Medroxyprogesterone Acetate Injection, IM, 150 mg/mL, packaged in 1 ml Single Dose Vial, RX Only, Ideal Pharmacy, 2333 Morris Ave, Union, NJ 07083
- Manufacturer
- Ideal Specialty Apothecary, Inc. dba Ideal Pharmacy
- Hazard
- sterility-assurance
- injectable-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27